Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 2
2004 5
2005 7
2006 5
2007 7
2008 12
2009 5
2010 7
2011 10
2012 3
2013 7
2014 2
2015 8
2016 6
2017 8
2018 10
2019 7
2020 12
2021 10
2022 14
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Vétizou M, et al. Among authors: chaput n. Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5. Science. 2015. PMID: 26541610 Free PMC article.
Tumour burden and efficacy of immune-checkpoint inhibitors.
Dall'Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Robert C, Besse B. Dall'Olio FG, et al. Among authors: chaput n. Nat Rev Clin Oncol. 2022 Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12. Nat Rev Clin Oncol. 2022. PMID: 34642484 Review.
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.
Bessede A, Marabelle A, Guégan JP, Danlos FX, Cousin S, Peyraud F, Chaput N, Spalato M, Roubaud G, Cabart M, Khettab M, Chaibi A, Rey C, Nafia I, Mahon FX, Soria JC, Italiano A. Bessede A, et al. Among authors: chaput n. Ann Oncol. 2022 Sep;33(9):909-915. doi: 10.1016/j.annonc.2022.05.010. Epub 2022 May 30. Ann Oncol. 2022. PMID: 35654248 Free article.
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Peyraud F, Guégan JP, Bodet D, Nafia I, Fontan L, Auzanneau C, Cousin S, Roubaud G, Cabart M, Chomy F, Le Loarer F, Chaput N, Danlos FX, Planchard D, Even C, Khettab M, Tselikas L, Besse B, Barlesi F, Soria JC, Marabelle A, Bessede A, Italiano A. Peyraud F, et al. Among authors: chaput n. Ann Oncol. 2022 Oct;33(10):1041-1051. doi: 10.1016/j.annonc.2022.07.001. Epub 2022 Jul 16. Ann Oncol. 2022. PMID: 35850444 Free article. Clinical Trial.
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
Loriot Y, Marabelle A, Guégan JP, Danlos FX, Besse B, Chaput N, Massard C, Planchard D, Robert C, Even C, Khettab M, Tselikas L, Friboulet L, André F, Nafia I, Le Loarer F, Soria JC, Bessede A, Italiano A. Loriot Y, et al. Among authors: chaput n. Ann Oncol. 2021 Nov;32(11):1381-1390. doi: 10.1016/j.annonc.2021.08.1748. Epub 2021 Aug 18. Ann Oncol. 2021. PMID: 34416362 Free article.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Mezquita L, et al. Among authors: chaput n. JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. JAMA Oncol. 2018. PMID: 29327044 Free PMC article.
Adoptive cell therapies in thoracic malignancies.
Lasvergnas J, Naigeon M, Chouahnia K, Zelek L, Chaput N, Duchemann B. Lasvergnas J, et al. Among authors: chaput n. Cancer Immunol Immunother. 2022 Sep;71(9):2077-2098. doi: 10.1007/s00262-022-03142-3. Epub 2022 Feb 7. Cancer Immunol Immunother. 2022. PMID: 35129636 Review.
Immunosenescence, inflammaging, and cancer immunotherapy efficacy.
Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, Besse B, Ferrara R, Chaput N, Baldini C. Rodriguez JE, et al. Among authors: chaput n. Expert Rev Anticancer Ther. 2022 Sep;22(9):915-926. doi: 10.1080/14737140.2022.2098718. Epub 2022 Jul 14. Expert Rev Anticancer Ther. 2022. PMID: 35815381 Review.
140 results